Good morning, everyone, and welcome to another working week. This week, however, ushers in a new era of sorts, as many of us greatly alter long-standing routines, at least for a while. Nonetheless, remaining focused can be a good thing, so please join us as we continue one of our own rituals — the celebrated brewing of the cup of stimulation. Meanwhile, we have once again assembled a few items of interest to help you get started. We hope your day goes well and you remain healthy.

An allegation that the Trump administration tried to secure exclusive rights to the production of an experimental coronavirus vaccine in Germany has revived concerns that countries worldwide might move to nationalize key supplies to respond to the growing pandemic, STAT explains. The allegation, first reported in German media and later echoed by that nation’s health minister, centered on the suggestion that the Trump administration sought to strike a deal with CureVac, a drug maker based in Germany but that also has operations in the U.S.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy